DE60310975T2 - Verwendung von epothilone zur behandlung hyperparathyreoidismus - Google Patents

Verwendung von epothilone zur behandlung hyperparathyreoidismus Download PDF

Info

Publication number
DE60310975T2
DE60310975T2 DE60310975T DE60310975T DE60310975T2 DE 60310975 T2 DE60310975 T2 DE 60310975T2 DE 60310975 T DE60310975 T DE 60310975T DE 60310975 T DE60310975 T DE 60310975T DE 60310975 T2 DE60310975 T2 DE 60310975T2
Authority
DE
Germany
Prior art keywords
parathyroid
treatment
epothilone
lower alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60310975T
Other languages
German (de)
English (en)
Other versions
DE60310975D1 (de
Inventor
A. Eugene Kenner WOLTERING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of DE60310975D1 publication Critical patent/DE60310975D1/de
Application granted granted Critical
Publication of DE60310975T2 publication Critical patent/DE60310975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60310975T 2002-10-15 2003-10-13 Verwendung von epothilone zur behandlung hyperparathyreoidismus Expired - Lifetime DE60310975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US418592P 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (2)

Publication Number Publication Date
DE60310975D1 DE60310975D1 (de) 2007-02-15
DE60310975T2 true DE60310975T2 (de) 2007-07-12

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310975T Expired - Lifetime DE60310975T2 (de) 2002-10-15 2003-10-13 Verwendung von epothilone zur behandlung hyperparathyreoidismus

Country Status (15)

Country Link
US (2) US20060142354A1 (enExample)
EP (1) EP1553938B1 (enExample)
JP (1) JP4672368B2 (enExample)
CN (1) CN1297269C (enExample)
AT (1) ATE350034T1 (enExample)
AU (1) AU2003267751A1 (enExample)
BR (1) BR0315293A (enExample)
CA (1) CA2501717C (enExample)
CY (1) CY1106385T1 (enExample)
DE (1) DE60310975T2 (enExample)
DK (1) DK1553938T3 (enExample)
ES (1) ES2279139T3 (enExample)
PT (1) PT1553938E (enExample)
SI (1) SI1553938T1 (enExample)
WO (1) WO2004035050A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1155689E (pt) * 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
HK1080768A1 (en) 2006-05-04
JP2006504751A (ja) 2006-02-09
DE60310975D1 (de) 2007-02-15
CN1703217A (zh) 2005-11-30
ES2279139T3 (es) 2007-08-16
CY1106385T1 (el) 2011-10-12
AU2003267751A1 (en) 2004-05-04
US20110152329A1 (en) 2011-06-23
EP1553938A1 (en) 2005-07-20
CA2501717A1 (en) 2004-04-29
CN1297269C (zh) 2007-01-31
ATE350034T1 (de) 2007-01-15
CA2501717C (en) 2012-09-18
BR0315293A (pt) 2005-08-30
PT1553938E (pt) 2007-03-30
DK1553938T3 (da) 2007-03-26
US20060142354A1 (en) 2006-06-29
SI1553938T1 (sl) 2007-06-30
WO2004035050A1 (en) 2004-04-29
JP4672368B2 (ja) 2011-04-20
EP1553938B1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE3590035C2 (de) Diphenhydramin enthaltende analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
DE3874917T2 (de) Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
DE69125714T2 (de) Zusammensetzung für die behandlung des humanen prostata adenokarzinom
DE69012261T2 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE69519937T2 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
EP0521388B1 (de) Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
EP1397138B1 (de) WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE60032517T2 (de) Heilmittel gegen durch endothelin verursachte erkrankungen
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE3343934A1 (de) M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels
DE3530767C2 (enExample)
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE3033545A1 (de) Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE60310975T2 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE69008466T2 (de) Verwendung des 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-Dimethyluracils zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Harnwegsverstopfungen.
DE69023939T2 (de) Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
EP0132595B1 (de) Tokolytisches Mittel
DE69903546T2 (de) Levosimendan für die behandlung von pulmonaler hypertonie
AT408719B (de) Mittel zur behandlung von hepatitis c

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN